Overview
FBLG market data
Price History
FBLG price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$8.35 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.60 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.62 – $12.80 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $6.5M · P/B 2.43.
Company News
FibroBiologics Says USPTO Issues US Patent Entitled Methods And Compositions For Treatment Of Type 1 Diabetes Using Fibroblasts In Facilitation Of Islet EngraftmentBenzinga · Aug 11, 2026, 12:39 PM
FibroBiologics Receives Patent From European Patent Office For Its Gene Therapy For The Regeneration Of Chondrocytes Or Cartilage Type CellsBenzinga · Aug 5, 2026, 12:33 PM
Snap To Rally More Than 217%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga · Aug 4, 2026, 11:52 AM
HC Wainwright & Co. Maintains Buy on FibroBiologics, Lowers Price Target to $6Benzinga · Aug 4, 2026, 10:15 AM
FibroBiologics shares are trading higher after the company reported better-than-expected Q2 EPS results.Benzinga · Aug 3, 2026, 6:02 PM
FibroBiologics, Inc. - Common Stock Q2 EPS $(0.66) Beats $(0.72) EstimateBenzinga · Jul 31, 2026, 9:38 PM
8-K filing — FibroBiologics, Inc. (FBLG)SEC EDGAR · Jul 24, 2026, 8:05 PM
FibroBiologics Completes Manufacturing Of Third Batch Of CYWC628 Drug Product For Ongoing Phase 1/2 Clinical Trial In Patients With Diabetic Foot UlcersBenzinga · Jul 7, 2026, 12:45 PM
FibroBiologics Commences Up To $9M Offering Of Common Shares, WarrantsBenzinga · Jun 26, 2026, 12:45 PM
FibroBiologics Receives U.S. Patent And Trademark Office Notice Of Allowance For Patented Application Entitled Therapeutic Use Of Fibroblasts In Wound HealingBenzinga · Jun 22, 2026, 12:35 PM